Temporal Pole Transcranial Alternating Current Stimulation for Children With Autism Spectrum Disorder
Launched by FEI LI · Jun 30, 2025
Trial Information
Current as of July 04, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two types of gentle brain stimulation—called transcranial alternating current stimulation (tACS) and transcranial temporal interference stimulation (tTIS)—to see if they are safe and helpful for children with autism spectrum disorder (ASD). The researchers want to find out if these treatments can improve symptoms related to social skills, language, thinking, and daily functioning. Children in the study will be divided into three groups: one group will receive tACS, another will receive tTIS, and a third group will continue with their usual rehabilitation therapies. The treatments will be given for five days, and the children will be checked for any side effects and improvements for up to four weeks after the treatment.
Children who might be eligible for this study are between 4 and 10 years old, have a confirmed diagnosis of autism, and have an intelligence level that meets a certain minimum standard. Children with metal implants, epilepsy, certain brain or heart conditions, or other serious health issues will not be able to join. If a child participates, families can expect a safe and closely monitored process where doctors and researchers will track how the brain stimulation affects symptoms and overall well-being. This study is not yet recruiting participants but aims to explore new ways to support children with autism through non-invasive treatments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Children aged 4-10 years
- • 2. Meeting the diagnostic criteria for ASD according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
- • 3. Diagnosis confirmed by the Autism Diagnostic Observation Schedule (ADOS) and/or the Autism Diagnostic Interview-Revised (ADI-R)
- • 4. Full Scale Intelligence Quotient (FSIQ) ≥50
- • 5. Signed informed consent form
- Exclusion Criteria:
- • 1. Individuals with metal implants in the body
- • 2. Individuals with neurological disorders such as epilepsy
- • 3. Those requiring surgical treatment due to structural abnormalities indicated by brain MRI examination
- • 4. Those diagnosed with genetic or chromosomal abnormalities
- • 5. Individuals with mental illness (such as mood disorders, etc.)
- • 6. Those with severe cardiac disease
- • 7. Individuals with increased intracranial pressure
- • 8. Those currently participating in other clinical trials
- • 9. Those who received new intervention protocols within 4 weeks prior to enrollment.
About Fei Li
Fei Li is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative clinical studies. With a strong focus on ethical standards and regulatory compliance, Fei Li collaborates with leading healthcare professionals and institutions to design and implement trials that address critical health challenges. The organization prioritizes patient safety and data integrity, leveraging cutting-edge methodologies and technologies to ensure robust results. Through a strategic approach to research and development, Fei Li aims to contribute significantly to the advancement of therapeutic options in various medical fields.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported